Infections caused by fungal pathogens pose a serious and steadily increasing threat to susceptible individuals worldwide1 with a specific impact on treatment of immunocompromised patients. Fungi represent a distinct kingdom among the Eukarya, making the design and validation of therapeutic compounds that may counteract fungal infections a highly challenging and unfortunately massively neglected field in the pharmaceutical pipeline.2 Mechanisms and determinants of fungal pathogenesis are far from being understood comprehensively but this is a pre-requisite to define what has been coined the human virulome of pathogenic fungi.3 As an infectious disease is commonly the outcome of a potential pathogen encountering a susceptible host, both sides of this intertwined interplay need to be studied with the aim to put fungal characteristics in the appropriate context of virulence.4 Therefore, suitable models of infection are an essential requirement when testing distinct features of the pathogen as virulence-determining factors or to validate therapeutic interventions such as efficiencies of antimycotic substances. Small vertebrates like mice, rats, rabbits, guinea pigs, or hamsters have been established extensively for such purposes, based on their relative convenience with respect to handling and manipulation. The in-depth knowledge of the murine immune system that is accompanied by its highly advanced molecular biology and genetic accessibility has cemented the prime role of mice as hosts in infection studies, serving as proxy for the susceptible human host that is confronted with fungal pathogens. Yet, financial, infrastructural, and especially ethical issues limit the implementation of mammalian infection models to study the virulome of fungi. Apart from this, following the course of infection in individual hosts to assess fungal burden, histopathology, or immune responses is generally hampered by the application of invasive procedures that usually require culling of the infected cohort animal-by-animal.
Addressing these aspects, Coste and co-workers describe in the recent issue of Virulence their efforts to combine 2 of the most recent developments in fungal infection research, that is the use of an alternative insect mini-host accompanied by the implementation of a suitable reporter system based on bioluminescence that allows longitudinal studies in single infected animals.5 Driven by the need for alternatives replacing mammalian systems to study fungal infections, established model organisms such as the zebrafish Danio rerio, the nematode Ceanorhabditis elegans or the soil amoeba Dictyostelium discoideum and Acanthamoeba castellanii have been validated in recent years to cover various characteristics of fungal virulence and host response.6-12 This has been complemented by making use of embryonated chicken eggs, which allowed virulence studies addressing relevant aspects such as invasion, dissemination, or immune reactions.13 In promoting such initiatives, invertebrate insect hosts have a long-standing tradition to elucidate mechanisms of immunity against fungal pathogens and virulence determinants, ranging from seminal early studies in the fruit fly Drosophila melanogaster that opened the field of receptor-mediated recognition of pathogen-associated molecular patterns, the so-called PAMPs, to recent ones in locusts that appear suitable to mimic invasion of the central nervous systems by pathogenic fungi.14-16 Due their ease of housing and handling and thereby obviating administrative as well as ethical concerns, insect larvae have emerged as most suitable for infection studies; this is accompanied by several other benefits, such as relatively low purchase costs, their survival at appropriate temperatures that support growth of fungal pathogens, or the feasibility of precise and non-traumatic inoculation with defined infectious doses due to their relatively large size.
For the opportunistic pathogen Candida albicans, the silkworm Bombyx mori or caterpillars of the tobacco hornworm Manduca sexta had been established most recently as suitable replacement hosts to monitor virulence traits, while larvae of the greater wax moth Galleria mellonella have served as predominant mini-host for Candida infections since the year 2000.17-19 These larvae lack an adaptive immune response but hold various hemocytes that eliminate invading pathogens via phagocytosis; moreover, humoral components of innate immunity, like antimicrobial peptides, are mounted upon infection, with differences being evident for the response against bacterial or fungal pathogens.20 Wax moth larvae have served to address various aspects of the host-fungus interplay in the context of pathogenesis, ranging from pattern recognition triggering nodulation to filamentation and other traits of virulence and even the efficiency of antifungals.21-23 A systematic analysis of C. albicans mutants impaired in the yeast-to-hyphal transition in both the murine systemic infection model as well as the Galleria system revealed a reliably good correlation,22 and studies with the yeast pathogen Cryptococcus neoformans or the human-pathogenic mold Aspergillus fumigatus have led to similar conclusions.24,25 A recent study from the Coste group however also demonstrated significant discrepancies between the 2 infection models.26 Yet, G. mellonella larvae have earned their merits in studying fungal infections that is only dampened by the evident lack of a reference genome sequence and missing tools of molecular biology for genetic engineering.
When following the course of disease and/or therapeutic treatment in an appropriate infection model system, crucial parameters such as symptomatic signs but also pathogen distribution and load need to be monitored. In this respect, sensitive reporter systems have been developed that are based on bioluminescence, i.e. photon emission conjunct with substrate oxidation that is catalyzed by light-generating enzymes. These so-called luciferases have evolved in prokaryotes as well as eukaryotes, and several enzymes of either origin are nowadays established, differing with respect to physico-chemical characteristics such as the nature of (co-)substrates, signal peak wavelength, or emission kinetics.27 Emitted photons are commonly detected by the use of highly sensitive charged coupled device (CCD) cameras to yield a quantitative read-out of bioluminescence. Accordingly, a longitudinal insight about pathogen distribution in the infected organism might be gained without the need for terminal inspection, which evidently reduces the number of hosts to be monitored. For fungal pathogens, several studies have demonstrated the usefulness of but also the limitations of bioluminescence imaging in murine infection systems.28-35 A major restriction lies in the obligate need for external substrate application, which is in contrast to bacterial pathogens that might be transformed with thoroughly characterized and adapted bioluminescence operons.36 Due to the orthogonality of such systems, these cannot be employed in fungal organisms, while eukaryotic bioluminescent systems are only characterized with respect to the luciferase activity but not substrate-generating pathways.
In the recent issue of Virulence, Eric Delarze and colleagues have described the fruitful combination of both approaches, employing Galleria mellonella larvae as hosts for infections by the human commensal Candida albicans and implementing bioluminescence as reporter read-out to enhance studies on virulence traits as well as antifungal treatment.5 By transferring a validated and optimized expression module for surface display of the luciferase enzyme from the copepod Gaussia princeps29 to a wild-type isolate and congenic deletion strains, bioluminescent signals could be quantified ex vivo from the pulp of infected and sacrificed larvae that correlated to fungal burdens deduced from colony forming units to some degree. Most importantly, the fungal infection could also be monitored over time in living wax moth larvae by using a non-toxic and water-soluble formulation of the substrate coelenterazine, WCTZ. This allowed in vivo kinetic studies of C. albicans infections in this alternative host and represents a step forward in elucidating virulence characteristics of this common yeast pathogen and in monitoring options for antifungal treatment. From this study, further perspectives emerge but also shortcomings and limitations of the system became evident: Obviously the described achievements pave the road for large scale studies to yield significant insights at high reliability without the need for infecting numerous cohorts of susceptible mice. This proof-of-concept study might also spark additional initiatives with other fungal pathogens for which bioluminescence as well as the wax moth larvae infection model had been successfully established. Yet, drawbacks emerge from the apparent lack of a standardized set of congenic C. albicans strains that carry the integrated reporter constructs at defined and identical numbers. Infecting wax moth larvae can also not reflect the various facets of C. albicans pathogenicity that range from superficial colonization to systemic dissemination. In this context, however, the Gaussia-derived bioluminescence system had been characterized exhaustingly in murine infection models to reveal shortcomings that may be associated with substrate instability, emission characteristics, or tissue penetration issues.29 Accordingly, the necessity of external substrate application in bioluminescence studies on fungal pathogens is still an unresolved issue that needs to be addressed to significantly further the field. The recent insights by Delarze et al., however, make a strong case for developing bioluminescence imaging approaches in alternative mini-hosts with the aim to study fungal virulence.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
References
- 1.Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012; 4:165rv13; PMID:23253612; http://dx.doi.org/ 10.1126/scitranslmed.3004404 [DOI] [PubMed] [Google Scholar]
- 2.Denning DW, Bromley MJ. Infectious Disease. How to bolster the antifungal pipeline. Science 2015; 347:1414-6; PMID:25814567; http://dx.doi.org/ 10.1126/science.aaa6097 [DOI] [PubMed] [Google Scholar]
- 3.Casadevall A. Cards of virulence and the global virulome for humans. Microbe 2006; 1:359-64 [Google Scholar]
- 4.Casadevall A, Pirofski LA. Microbiology: Ditch the term pathogen. Nature 2014; 516:165-6; PMID:25503219; http://dx.doi.org/ 10.1038/516165a [DOI] [PubMed] [Google Scholar]
- 5.Delarze E, Francoise I, Sanglard D, Coste AT. Adaptation of a Gaussia princeps luciferase reporter system in Candida albicans for in vivo detection in the Galleria mellonella infection model. Virulence 2015; 6:684-693; PMID:26305489 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Chao CC, Hsu PC, Jen CF, Chen IH, Wang CH, Chan HC, Tsai PW, Tung KC, Lan CY, Chuang YJ. Zebrafish as a model host for Candida albicans infection. Infect Immun 2010; 78:2512-21; PMID:20308295; http://dx.doi.org/ 10.1128/IAI.01293-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Pukkila-Worley R, Peleg AY, Tampakakis E, Mylonakis E. Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model. Eukaryot Cell 2009; 8:1750-8; PMID:19666778; http://dx.doi.org/ 10.1128/EC.00163-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tampakakis E, Okoli I, Mylonakis E. AC elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat Protoc 2008; 3:1925-31; PMID:19180076; http://dx.doi.org/ 10.1038/nprot.2008.193 [DOI] [PubMed] [Google Scholar]
- 9.Hillmann F, Novohradska S, Mattern DJ, Forberger T, Heinekamp T, Westermann M, Winckler T, Brakhage AA. Virulence determinants of the human pathogenic fungus Aspergillus fumigatus protect against soil amoeba predation. Environ Microbiol 2015; 17:2858-69; PMID:25684622; http://dx.doi.org/ 10.1111/1462-2920.12808 [DOI] [PubMed] [Google Scholar]
- 10.Steenbergen JN, Nosanchuk JD, Malliaris SD, Casadevall A. Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun 2003; 71:4862-72; PMID:12933827; http://dx.doi.org/ 10.1128/IAI.71.9.4862-4872.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chrisman CJ, Alvarez M, Casadevall A. Phagocytosis of Cryptococcus neoformans by, and nonlytic exocytosis from, Acanthamoeba castellanii. Appl Environ Microbiol 2010; 76:6056-62; PMID:20675457; http://dx.doi.org/ 10.1128/AEM.00812-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A 2001; 98:15245-50; PMID:11742090; http://dx.doi.org/ 10.1073/pnas.261418798 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jacobsen ID, Grosse K, Hube B. Embryonated chicken eggs as alternative infection model for pathogenic fungi. Methods Mol Biol 2012; 845:487-96; PMID:22328397; http://dx.doi.org/ 10.1007/978-1-61779-539-8_34 [DOI] [PubMed] [Google Scholar]
- 14.Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-83; PMID:8808632; http://dx.doi.org/ 10.1016/S0092-8674(00)80172-5 [DOI] [PubMed] [Google Scholar]
- 15.Mortazavi PN, Goldsworthy G, Kirk R, Khan NA. Acanthamoeba produces disseminated infection in locusts and traverses the locust blood-brain barrier to invade the central nervous system. BMC Microbiol 2010; 10:186; PMID:20615207; http://dx.doi.org/ 10.1186/1471-2180-10-186 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Siddiqui R, Edwards-Smallbone J, Flynn R, Khan NA. Next generation of non-mammalian blood-brain barrier models to study parasitic infections of the central nervous system. Virulence 2012; 3:159-63; PMID:21921682; http://dx.doi.org/ 10.4161/viru.17631 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Diezmann S. Of caterpillars and yeasts: Introducing a new model system for the study of fungal virulence. 19th ISHAM Congress 2015. Available at: http://figshare.com/articles/Of_caterpillars_and_yeasts_Introducing_a_new_model_system_for_the_study_of_fungal_virulence/1424584; accessed September 14, 2015 [Google Scholar]
- 18.Hanaoka N, Takano Y, Shibuya K, Fugo H, Uehara Y, Niimi M. Identification of the putative protein phosphatase gene PTC1 as a virulence-related gene using a silkworm model of Candida albicans infection. Eukaryot Cell 2008; 7:1640-8; PMID:18708562; http://dx.doi.org/ 10.1128/EC.00129-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Cotter G, Doyle S, Kavanagh K. Development of an insect model for the in vivo pathogenicity testing of yeasts. FEMS Immunol Med Microbiol 2000; 27:163-9; PMID:10640612; http://dx.doi.org/ 10.1111/j.1574-695X.2000.tb01427.x [DOI] [PubMed] [Google Scholar]
- 20.Mak P, Zdybicka-Barabas A, Cytrynska M. A different repertoire of Galleria mellonella antimicrobial peptides in larvae challenged with bacteria and fungi. Dev Comp Immunol 2010; 34:1129-36; PMID:20558200; http://dx.doi.org/ 10.1016/j.dci.2010.06.005 [DOI] [PubMed] [Google Scholar]
- 21.Dunphy GB, Oberholzer U, Whiteway M, Zakarian RJ, Boomer I. Virulence of Candida albicans mutants toward larval Galleria mellonella (Insecta, Lepidoptera, Galleridae). Can J Microbiol 2003; 49:514-24; PMID:14608387; http://dx.doi.org/ 10.1139/w03-064 [DOI] [PubMed] [Google Scholar]
- 22.Brennan M, Thomas DY, Whiteway M, Kavanagh K. Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae. FEMS Immunol Med Microbiol 2002; 34:153-7; PMID:12381467; http://dx.doi.org/ 10.1111/j.1574-695X.2002.tb00617.x [DOI] [PubMed] [Google Scholar]
- 23.Kelly J, Kavanagh K. Caspofungin primes the immune response of the larvae of Galleria mellonella and induces a non-specific antimicrobial response. J Med Microbiol 2011; 60:189-96; PMID:20947665; http://dx.doi.org/ 10.1099/jmm.0.025494-0 [DOI] [PubMed] [Google Scholar]
- 24.Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 2005; 73:3842-50; PMID:15972469; http://dx.doi.org/ 10.1128/IAI.73.7.3842-3850.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Slater JL, Gregson L, Denning DW, Warn PA. Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol 2011; 49 Suppl 1:S107-13; PMID:20950221; http://dx.doi.org/ 10.3109/13693786.2010.523852 [DOI] [PubMed] [Google Scholar]
- 26.Amorim-Vaz S, Delarze E, Ischer F, Sanglard D, Coste AT. Examining the virulence of Candida albicans transcription factor mutants using Galleria mellonella and mouse infection models. Front Microbiol 2015; 6:367; PMID:25999923 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Brock M. Application of bioluminescence imaging for in vivo monitoring of fungal infections. Int J Microbiol 2012; 2012:956794; PMID:22121368; http://dx.doi.org/ 10.1155/2012/956794 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Donat S, Hasenberg M, Schafer T, Ohlsen K, Gunzer M, Einsele H, Löffler J, Beilhack A, Krappmann S. Surface display of Gaussia princeps luciferase allows sensitive fungal pathogen detection during cutaneous aspergillosis. Virulence 2012; 3:51-61; PMID:22286700; http://dx.doi.org/ 10.4161/viru.3.1.18799 [DOI] [PubMed] [Google Scholar]
- 29.Enjalbert B, Rachini A, Vediyappan G, Pietrella D, Spaccapelo R, Vecchiarelli A, Brown AJ, d'Enfert C. A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections. Infect Immun 2009; 77:4847-58; PMID:19687206; http://dx.doi.org/ 10.1128/IAI.00223-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Galiger C, Brock M, Jouvion G, Savers A, Parlato M, Ibrahim-Granet O. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. Antimicrob Agents Chemother 2013; 57:3046-59; PMID:23587947; http://dx.doi.org/ 10.1128/AAC.01660-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Ibrahim-Granet O, Jouvion G, Hohl TM, Droin-Bergere S, Philippart F, Kim OY, Adib-Conquy M, Schwendener R, Cavaillon JM, Brock M. In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiol 2010; 10:105; PMID:20377900; http://dx.doi.org/ 10.1186/1471-2180-10-105 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kucharíková S, Vande Velde G, Himmelreich U, Van Dijck P. Candida albicans biofilm development on medically-relevant foreign bodies in a mouse subcutaneous model followed by bioluminescence imaging. J Vis Exp 2015; 95:e52239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Mosci P, Pericolini E, Gabrielli E, Kenno S, Perito S, Bistoni F, d'Enfert C, Vecchiarelli A. A novel bioluminescence mouse model for monitoring oropharyngeal candidiasis in mice. Virulence 2013; 4:250-4; PMID:23334179; http://dx.doi.org/ 10.4161/viru.23529 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Papon N, Courdavault V, Lanoue A, Clastre M, Brock M. Illuminating fungal infections with bioluminescence. PLoS Pathog 2014; 10:e1004179; PMID:25010008; http://dx.doi.org/ 10.1371/journal.ppat.1004179 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Vande Velde G, Kucharikova S, Schrevens S, Himmelreich U, Van Dijck P. Towards non-invasive monitoring of pathogen-host interactions during Candida albicans biofilm formation using in vivo bioluminescence. Cell Microbiol 2014; 16:115-30; PMID:23962311; http://dx.doi.org/ 10.1111/cmi.12184 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Francis KP, Yu J, Bellinger-Kawahara C, Joh D, Hawkinson MJ, Xiao G, Purchio TF, Caparon MG, Lipsitch M, Contag PR. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun 2001; 69:3350-8; PMID:11292758; http://dx.doi.org/ 10.1128/IAI.69.5.3350-3358.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]